3D Laboratory Cell Growth System Should Speed Up MS Remyelination Research
A physical scaffold that allows lab-grown brain cells to grow in a three-dimensional manner is giving scientists a whole new…
Articles by Patricia Silva, PhD
Firefighter with Relapsing MS on Ocrevus: ‘I Have Really Good Days and I Have Bad Days’
Texas firefighter Wayne Donovan is among the estimated 250,000 to 350,000 Americans with multiple sclerosis (MS). He enrolled in a clinical…
Importance of Elevators for Universal Housing
You might think that the Fair Housing Act required multifamily buildings to have elevators,…
ABLE Act Improvements Reintroduced in Congress
The ABLE Act improvement bills were reintroduced into Congress this week and referred to committee on April 4. The bills died in…
Canada, World’s Multiple Sclerosis Capital, Launches 3-Way Collaboration to Research MS Progression
Three Canadian entities — Toronto-based Biogen Canada and the MS Society of Canada, and Montreal-based Brain Canada — have jointly invited researchers to…
‘Adequate and Rapid Delivery’ of Ocrevus Expected, Says Genentech Director in Interview
Ocrevus (ocrelizumab), now approved for both relapsing and primary progressive multiple sclerosis (MS), is expected to become available in the…
Transcript of Interview with Dr. Robert Lisak, a Neurologist and MS Expert, About Ocrevus
Here is a transcript of the Multiple Sclerosis News Today interview about Ocrevus (ocrelizumab) with Dr. Robert…
Ocrevus Holds Promise, But Needs to Prove Itself in ‘Long Term,’ Says Dr. Robert Lisak with CMSC
Interest in Ocrevus (ocrelizumab), the first FDA-approved treatment for both relapsing and primary progressive multiple sclerosis, is running high among…
Research on Faulty Stem Cells Suggests MS Patients Need Tailored Therapies
Brain stem cells from primary progressive multiple sclerosis (PPMS) patients lack the ability to repair brain damage and to trigger…
What Every MS Patient Should Know About Ocrevus and Its Use
With the recent approval of Ocrevus (ocrelizumab) for both primary progressive and relapsing multiple sclerosis (MS), interest in the…
Diplomat Pharmacy Chosen to Dispense Ocrevus to MS Patients Across US
Diplomat Pharmacy, the largest independent specialty pharmacy in the U.S., has been selected to dispense Ocrevus (ocrelizumab), a limited-distribution…
Hope, But No Cheers Yet, Voiced by MS Groups in Europe and Canada Waiting on Own Ocrevus Decision
American patient groups and neurologists have clearly been giving Ocrevus (ocrelizumab) plenty of attention since news of its approval landed, as…
Excitement to Cautious Optimism — Reactions to Approval of Ocrevus
The historic approval of Ocrevus (ocrelizumab), the first-ever treatment for primary progressive multiple sclerosis (MS), set off ripples in…
Dedicated Handicapped Parking is About Availability, Not Cost
Being disabled by MS does not have many advantages. One — free city street parking…
FDA Approves Ocrevus as 1st MS Treatment for Both Relapsing and Primary Progressive Forms
At long last, and for the first time in medical history, people with both relapsing and primary progressive forms of multiple…
CGEN-15001, Compugen’s Tolerance-Inducing Autoimmune Therapy for MS, Is Subject of Two Presentations
CGEN-15001, which could become the first tolerance-inducing therapy for multiple sclerosis (MS) and other autoimmune conditions, is on the agenda…
Ocrevus’ Journey from Defiant Idea to Game-Changing Treatment
Twenty years ago, the idea that B-cell depletion could treat multiple sclerosis would have been greeted with a hearty laugh by any well-respected…
Two Genes Team Up to Increase Risk of Multiple Sclerosis, Study Indicates
A person unlucky enough to have two specific gene variants is at significantly higher risk of developing multiple sclerosis (MS),…
National MS Society-Sponsored Group Creates Tool Set to Measure Outcomes in MS Clinical Trials
Four newly published articles, the focused work of a group of researchers, evaluate the validity of four outcome measures commonly…
The Countdown Is on for This Year’s MuckFest MS Fundraising Series
The 2017 version of MuckFest MS, the five-kilometer fundraising mud-run series, will begin in a few weeks. The event, organized…
Worldwide Clinical Trials to Host Free Webinar on Biosimilars for MS Awareness Month
Worldwide Clinical Trials has added two webinars to its free webinar series — the first to observe Multiple Sclerosis Awareness Month in March…
Swallowing Problems in MS That Lead to Pneumonia Need Attention, Professor Says
Swallowing difficulties and reduced cough are a major, yet commonly overlooked, issue in patients with multiple sclerosis and other brain…
Kadimastem Obtains US Patent for Neurodegenerative Disease Stem Cell Technology
The United States has granted a patent to Kadimastem’s stem cell-based technology for treating multiple sclerosis (MS) and other diseases of…
Physician Assisted Suicide’s Appeal to MS Patients in Unbearable Pain Highlights Urgency in Treating Depression
Half of the more than 7,500 multiple sclerosis (MS) patients responding to a recent survey revealed they’d consider physician-assisted suicide if…
Alkermes Begins Phase 3 Study of ALKS 8700 as Relapsing MS Treatment
Alkermes has started a Phase 3 clinical trial evaluating ALKS 8700, the oral monomethyl fumarate (MMF) prodrug it is…
In Reversal, NICE Recommends Relapsing MS Treatment Zinbryta for England and Wales
The United Kingdom’s National Institute for Health and Care Excellence (NICE) has cleared its initial doubts and now recommends Zinbryta…
Ocrevus and the Hope of ‘Ending MS Forever’: Interview with MS Society’s Tim Coetzee
The potential approval of Ocrevus (ocrelizumab) this month supports the idea that, someday, a world free of multiple sclerosis (MS) is…
Full Transcript of Interview with Tim Coetzee of the National MS Society
Here is a transcript of Multiple Sclerosis News Today‘s interview with Dr. Tim Coetzee — chief advocacy, services and research officer…
Discovery of T-cells’ Role in Myelin Regeneration Could Lead to Therapies That Mimic Processes
Regulatory T-cells in the central nervous system trigger the maturation of stem cells that increase the production of myelin at…
Acorda Launches Interactive and Talking ‘MS Awareness Facts’ Alexa Service for March
In recognition of multiple sclerosis (MS) awareness month, Acorda Therapeutics has launched its Alexa skill, called MS Awareness Facts.